Bayer Suspends Marketing of Trasyol

Jamie G. Goldstein

Attorney
(866) 735-1102 Ext 626

0 CommentsPrint ArticleSubscribe

The FDA announced today that it has requested Bayer Pharmaceuticals Corporation to suspend its marketing of Traysol. Bayer has agreed to the suspension. Traysol, is used to control patient bleeding during heart surgery, but recent studies have suggested it can cause patients an increased risk of death.

The FDA and Bayer are currently working to phase out Traysdol without causing a market shortage due to the few other drug treatments currently available. This suspension of the drug comes after a December 2006 change in the Traysdol's label warning patients of potential kidney damage.

It is too early to determine how many people have had adverse reactions to Traysdol, but if you or someone you know was given Traysdol during heart surgery and died as a result of the surgery or had serious side effects, contact an attorney immediately. You may be able to recover if the Traysdol caused the adverse event.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.